<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="0" ids="50276">Topoisomerase I inhibitors</z:chebi>, like topotecan, have activity in <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>9-<z:chebi fb="13" ids="29785">Nitro</z:chebi>-<z:chebi fb="0" ids="27656">camptothecin</z:chebi> (9-NC) is a new oral topoisomerase inhibitor with a good safety profile </plain></SENT>
<SENT sid="2" pm="."><plain>The aims of the current study were to evaluate the activity and safety of 9-NC in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Adults with a diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (n = 12) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> (n = 32) received 9-NC 2 mg/m(2) orally daily 5 days a week, every 4 to 6 weeks </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Overall, 5 (11%) patients achieved complete response (CR), 7 (16%) had a partial response (PR), and 6 (14%) had hematologic improvement (HI), for an overall response rate of 41% </plain></SENT>
<SENT sid="5" pm="."><plain>The response rate was similar in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Severe (Grade 3-4) side effects included <z:hpo ids='HP_0002017'>nausea and vomiting</z:hpo> (7%), <z:hpo ids='HP_0002014'>diarrhea</z:hpo> (18%), other gastrointestinal toxicities (5%), and genitourinary toxicities (12%) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: 9-NC is active in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>The paucity of available therapies in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> makes 9-NC a good candidate for further studies as a single agent, or in combination with <z:chebi fb="0" ids="50131">decitabine</z:chebi>, 5-<z:chebi fb="0" ids="2038">azacitidine</z:chebi> or <z:chebi fb="0" ids="28680">cytarabine</z:chebi> </plain></SENT>
</text></document>